Dr sc. Miroslav Savić

Др сц. Мирослав Савић

Zvanje: redovni profesor
Organizaciona jedinicaKatedra za farmakologiju
Prostorija: B001
Telefon: +381 11 3951-280
Fax: +381 11 3972-840
Emailmiroslav@pharmacy.bg.ac.rs

CV


Miroslav M. Savić, rođen 1973. u Kraljevu, diplomirao je na Farmaceutskom fakultetu Univerziteta u Beogradu 1997. Na Medicinskom fakultetu Univerziteta u Beogradu odbranio je magistarsku tezu 2002. godine, a doktorsku disertaciju 2004. godine, iz oblasti Farmakologija.

Zaposlen je na Farmaceutskom fakultetu Univerziteta u Beogradu od 1998. godine, a od 2015. godine je redovni profesor na Katedri za farmakologiji. Mentor je osam odbranjenih doktorskih disertacija. Rukovodilac je nacionalnih projekata koje finansira Ministarstvo prosvete, nauke i tehnološkog razvoja Srbije, u periodu 2006-2010. i 2011-2019. godine, kao i projekta Ideje Fonda za nauku Republike Srbije u periodu 2022-2024. (Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma 2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platforms). Bio je koordinator dva bilateralna istraživačka projekta između Austrije i Srbije (2016-2017 i 2018-2020). Rukovodilac je radnog paketa u okviru H2020 projekta "Preklinička predikcija neželjenih lekova na nervni sistem" u liniji Inicijative za inovativne lekove, za period 2019-2022.

Ko-autor je 61 rada sa SCI liste. Prema Scopus bazi ukupan broj citata bez heterocitata je 1186, a h indeks 22. Inventor je dva publikovana međunarodna patenta. Član je Komisije za lekove Agencije za lekove i medicinska sredstva, Etičkog odbora Republike Srbije, Matičnog odbora za medicinske nauke Republike Srbije.

Glavna ekspertiza istraživačke grupe koju vodi Miroslav Savić fokusirana je na tehnike eksperimentalne analize ponašanja oglednih životinja (miševi, pacovi). Pored bihejvioralne farmakologije, istraživačka grupa sprovodi farmakokinetička istraživanja, metode neurohemije i različite molekularno-biološke tehnike, koje uključuju i rad na neuralnim ćelijama. Istraživanja su usmerena na modelovanje neuropsihijatrijskih poremećaja kao što su anksiozni poremećaji, autizam, depresija, shizofrenija, Alzheimer-ova bolest, kao i na otkriće i razvoj lekova u oblasti neuropsihofarmakologije. Ova istraživanja se sprovode u kontinuiranoj saradnji sa inostranim laboratorijama (SAD, Austrija, Kanada).

 
  • Aranđelović J, Santrač A, Batinić B, Todorović L, Ahmed Khan MZ, Rashid F, Poe MM, Obradović A, Cook JM, Savić MM. Positive and Negative Selective Allosteric Modulators of α5 GABAA Receptors: Effects on Emotionality, Motivation, and Motor Function in the 5xFAD Model of Alzheimer's Disease. J Alzheimers Dis. 2021;84(3):1291-1302. doi: 10.3233/JAD-215079.
  • Santrač A, Batinić B, Stamenić TT, Aranđelović J, Sharmin D, Knutson DE, Cook JM, Savić MM. Positive modulation of α5GABAA receptors leads to dichotomous effects in rats on memory pattern and GABRA5 expression in prefrontal cortex and hippocampus. Behav Brain Res. 2022 Jan 7;416:113578. doi: 10.1016/j.bbr.2021.113578.
  • Andronis C, Silva JP, Lekka E, Virvilis V, Carmo H, Bampali K, Ernst M, Hu Y, Loryan I, Richard J, Carvalho F, Savić MM. Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis. Arch Toxicol. 2020 Aug;94(8):2829-2845. doi: 10.1007/s00204-020-02788-1
  • Vasović D, Divović B, Treven M, Knutson DE, Steudle F, Scholze P, Obradović A, Fabjan J, Brković B, Sieghart W, Ernst M, Cook JM, Savić MM. Trigeminal neuropathic pain development and maintenance in rats are suppressed by a positive modulator of α6 GABAA receptors. Eur J Pain. 2019 May;23(5):973-984. doi: 10.1002/ejp.1365.
  • Sieghart W, Savić MM. International Union of Basic and Clinical Pharmacology. CVI: GABAA Receptor Subtype- and Function-selective Ligands: Key Issues in Translation to Humans. Pharmacol Rev. 2018 Oct;70(4):836-878. doi: 10.1124/pr.117.014449.
  • Knutson DE, Kodali R, Divović B, Treven M, Stephen MR, Zahn NM, Dobričić V, Huber AT, Meirelles MA, Verma RS, Wimmer L, Witzigmann C, Arnold LA, Chiou LC, Ernst M, Mihovilovic MD, Savić MM, Sieghart W, Cook JM. Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability. J Med Chem. 2018 Mar 22;61(6):2422-2446. doi: 10.1021/acs.jmedchem.7b01664.
  • Joksimović S, Divljaković J, Van Linn ML, Varagic Z, Brajković G, Milinković MM, Yin W, Timić T, Sieghart W, Cook JM, Savić MM. Benzodiazepine-induced spatial learning deficits in rats are regulated by the degree of modulation of α1 GABA(A) receptors. Eur Neuropsychopharmacol. 2013 May;23(5):390-9. doi: 10.1016/j.euroneuro.2012.05.003.
  • Savić MM, Majumder S, Huang S, Edwankar RV, Furtmüller R, Joksimović S, Clayton T Sr, Ramerstorfer J, Milinković MM, Roth BL, Sieghart W, Cook JM. Novel positive allosteric modulators of GABAA receptors: do subtle differences in activity at alpha1 plus alpha5 versus alpha2 plus alpha3 subunits account for dissimilarities in behavioral effects in rats? Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):376-86. doi: 10.1016/j.pnpbp.2010.01.004.
  • Savić MM, Milinković MM, Rallapalli S, Clayton T Sr, Joksimović S, Van Linn M, Cook JM. The differential role of alpha1- and alpha5-containing GABA(A) receptors in mediating diazepam effects on spontaneous locomotor activity and water-maze learning and memory in rats. Int J Neuropsychopharmacol. 2009 Oct;12(9):1179-93. doi: 10.1017/S1461145709000108.
  • Savić MM, Huang S, Furtmüller R, Clayton T, Huck S, Obradović DI, Ugresić ND, Sieghart W, Bokonjić DR, Cook JM. Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists? Neuropsychopharmacology. 2008 Jan;33(2):332-9. doi: 10.1038/sj.npp.1301403.